Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026
M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact pharminent June 17, 2026
Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
Clinical Data Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease pharminent June 15, 2026
Clinical Data Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy pharminent June 15, 2026
Manufacturing FDA imposes import alert on Indian plant after inspectors flag GMP failings pharminent June 12, 2026
Clinical Data Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win pharminent June 12, 2026
Policy / Pricing How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market pharminent June 11, 2026
Policy / Pricing Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026 pharminent June 11, 2026
M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026
Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026
M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market pharminent June 11, 2026
Regulatory Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug pharminent June 10, 2026
M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project pharminent June 9, 2026
Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026
M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026
Regulatory ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval pharminent June 9, 2026
Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia pharminent June 9, 2026
